EyePoint Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of EyePoint Pharmaceuticals generated cash of $1,875,000, which is more than the previous year. Cash used in financing activities reached the amount of $187,070,000 last year. Net change in cash is therefore $185,630,000.
Cash Flow
| 2014 | -10.67M | 66K | 19.04M |
|---|---|---|---|
| 2015 | 10.29M | -6.73M | 235K |
| 2016 | -16.31M | -4.46M | 16.99M |
| 2017 | -20.49M | 13.57M | 8.50M |
| 2018 | -21.90M | -16.88M | 60.67M |
| 2019 | -56.69M | -213K | 33.86M |
| 2020 | -14.43M | -362K | 37.49M |
| 2021 | -50.09M | -33.12M | 216.90M |
| 2022 | -65.00M | -17.26M | -690K |
| 2023 | 1.87M | -3.31M | 187.07M |
EYPT Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 95.63M | 178.74M | 45.05M | 22.36M | 45.41M | 17.04M | 15.31M | 19.12M | 15.33M | 6.89M |
Operating activities | ||||||||||
Net income | -70.79M | -102.25M | -58.41M | -45.39M | -56.79M | -53.17M | -18.48M | -21.54M | 6.34M | -13.35M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 464K | 2.44M | 2.77M | 2.64M | 2.60M | 1.14M | 815K | 908K | 882K | 917K |
Stock-based compensation expense | 12.05M | 14.17M | 7.44M | 5.54M | 4.56M | 0 | 2.70M | 2.45M | 2.16M | 1.96M |
| Deferred income tax benefit | 12.05M | 14.17M | 7.44M | 5.54M | 4.56M | 0 | 2.70M | 2.45M | 2.16M | 1.96M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 14.43M | -2.66M | -10.60M | 4.84M | -15.30M | 7K | 219K | 116K | -124K | 103K |
Inventories | -1.55M | -760K | 1.34M | -3.2M | -1.85M | -759K | 551K | 1.22M | 917K | 729K |
Accounts payable | 1.51M | 1.19M | 8.47M | 1.87M | 4.59M | 1.74M | -346K | 626K | 292K | -213K |
Cash generated by operating activities | 1.87M | -65.00M | -50.09M | -14.43M | -56.69M | -21.90M | -20.49M | -16.31M | 10.29M | -10.67M |
Investing activities | ||||||||||
Purchases Of Investments | -55.11M | -139.11M | -32.96M | 0 | 0 | 0 | -5.05M | -17.51M | -10.22M | -2.96M |
Investments In Property Plant And Equipment | -3.48M | -2.15M | -156K | -362K | -213K | -108K | -147K | -113K | -161K | -248K |
Acquisitions Net | -168K | -558K | 0 | 0 | 0 | -16.78M | -16.78M | 33K | 0 | 78K |
Cash generated by investing activities | -3.31M | -17.26M | -33.12M | -362K | -213K | -16.88M | 13.57M | -4.46M | -6.73M | 66K |
Financing activities | ||||||||||
Common Stock Issued | 226.17M | 0 | 216.82M | 49.91M | 22.62M | 41.51M | 41.51M | 16.5M | 16.5M | 18.05M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -295K | -150K | -90K | 0 | -195K | 0 | 0 | 0 | 0 |
Repayments of term debt | -40.51M | 2.10M | -146K | -13.84M | 30M | -20M | 20M | 0 | 0 | 0 |
Cash used in financing activities | 187.07M | -690K | 216.90M | 37.49M | 33.86M | 60.67M | 8.50M | 16.99M | 235K | 19.04M |
Net Change In Cash | 185.63M | -82.96M | 133.68M | 22.69M | -23.04M | 21.87M | 1.58M | -3.80M | 3.78M | 8.43M |
Cash at end of period | 281.26M | 95.78M | 178.74M | 45.05M | 22.36M | 38.92M | 16.89M | 15.31M | 19.12M | 15.33M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |